Most-Upgraded StocksMost-UpgradedNYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free EW Stock Alerts $87.73 +0.77 (+0.89%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$86.76▼$87.9250-Day Range$84.87▼$95.5652-Week Range$60.57▼$96.12Volume2.66 million shsAverage Volume2.89 million shsMarket Capitalization$52.81 billionP/E Ratio38.14Dividend YieldN/APrice Target$91.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Edwards Lifesciences alerts: Email Address Edwards Lifesciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.53 Rating ScoreUpside/Downside4.6% Upside$91.73 Price TargetShort InterestHealthy1.75% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.47Based on 22 Articles This WeekInsider TradingSelling Shares$17.17 M Sold Last QuarterProj. Earnings Growth11.96%From $2.76 to $3.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.37 out of 5 starsMedical Sector111th out of 909 stocksSurgical Appliances & Supplies Industry6th out of 18 stocks 2.3 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.75% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 0.67%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.5 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Edwards Lifesciences this week, compared to 11 articles on an average week.Search InterestOnly 6 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows50 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 16% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,166,254.00 in company stock.Percentage Held by InsidersOnly 1.27% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 11.96% in the coming year, from $2.76 to $3.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 38.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 38.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 238.51.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 7.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Edwards Lifesciences Stock (NYSE:EW)Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesApril 16, 2024 | insidertrades.comThe 5 Stocks Most Sold By Insiders This Year (EW)April 9, 2024 | insidertrades.comEdwards Lifesciences Co. (NYSE:EW) VP Sells $1,329,408.00 in StockApril 24, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 5, 2024 | insidertrades.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) Director Sells 29,350 Shares of StockApril 2, 2024 | insidertrades.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) CFO Sells 7,255 Shares of StockApril 23, 2024 | finance.yahoo.comDexCom (DXCM) to Report Q1 Earnings: What's in the Cards?April 20, 2024 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) to Post Q1 2024 Earnings of $0.65 Per Share, Leerink Partnrs ForecastsApril 19, 2024 | americanbankingnews.comBrokers Set Expectations for Edwards Lifesciences Co.'s Q1 2025 Earnings (NYSE:EW)April 24, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 18, 2024 | businesswire.comEdwards Lifesciences to Host Earnings Conference Call on April 25, 2024April 18, 2024 | americanbankingnews.comEdwards Lifesciences (EW) to Release Quarterly Earnings on ThursdayApril 17, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Edwards Lifesciences (EW)April 17, 2024 | finance.yahoo.comIs a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?April 16, 2024 | finance.yahoo.comZacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERISApril 16, 2024 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Price Target Raised to $101.00 at Royal Bank of CanadaApril 11, 2024 | markets.businessinsider.comWhat Analysts Are Saying About Edwards Lifesciences StockApril 10, 2024 | investing.comEdwards Lifesciences exec sells over $1.1m in company stockApril 7, 2024 | businesswire.comStudy of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing ItApril 5, 2024 | markets.businessinsider.comEvercore ISI Remains a Hold on Edwards Lifesciences (EW)April 3, 2024 | finance.yahoo.comAre Robust Financials Driving The Recent Rally In Edwards Lifesciences Corporation's (NYSE:EW) Stock?April 2, 2024 | msn.comAbbott's heart valve repair device gains US FDA approvalApril 2, 2024 | benzinga.com$100 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth This Much TodayApril 2, 2024 | seekingalpha.comBoston Scientific: The Market's Newest Mega-Cap Needs A BreatherApril 2, 2024 | reuters.comApple, Google again lose lawsuit challenging US patent-review policyMarch 30, 2024 | msn.comIMF confirms increasing Egypt's bailout loan to $8 billionMarch 30, 2024 | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) is largely controlled by institutional shareholders who own 83% of the companyMarch 25, 2024 | finance.yahoo.comAre Medical Stocks Lagging Edwards Lifesciences (EW) This Year?See More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/06/2024Today4/24/2024Next Earnings (Confirmed)4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$91.73 High Stock Price Target$107.00 Low Stock Price Target$57.00 Potential Upside/Downside+4.6%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)$2.30 Trailing P/E Ratio38.14 Forward P/E Ratio31.79 P/E Growth4.26Net Income$1.40 billion Net Margins23.35% Pretax Margin26.61% Return on Equity23.56% Return on Assets16.81% Debt Debt-to-Equity Ratio0.09 Current Ratio3.38 Quick Ratio2.40 Sales & Book Value Annual Sales$6.00 billion Price / Sales8.79 Cash Flow$2.82 per share Price / Cash Flow31.10 Book Value$11.08 per share Price / Book7.92Miscellaneous Outstanding Shares601,930,000Free Float594,283,000Market Cap$52.81 billion OptionableOptionable Beta1.05 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 56)CEO & Director Comp: $2.27MMr. Scott B. Ullem (Age 57)Corporate VP & CFO Comp: $1.35MMr. Donald E. Bobo Jr. (Age 62)Corporate Vice President of Strategy & Corporate Development Comp: $1.27MMr. Larry L. Wood (Age 58)Corporate VP and Group President of TAVR & Surgical Structural Heart Comp: $1.49MDr. Todd J. Brinton FACCM.D., Corporate VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVice President of Investor RelationsMr. Arnold A. Pinkston (Age 65)Corporate VP & General Counsel Mr. Dirksen J. LehmanCorporate Vice President of Public AffairsMs. Christine Z. McCauley (Age 59)Corporate Vice President of Human Resources Mr. Gary I. Sorsher (Age 59)Senior Vice President of Quality & Regulatory Compliance More ExecutivesKey CompetitorsIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNDexComNASDAQ:DXCMCencoraNYSE:CORView All CompetitorsInsiders & InstitutionsFifth Third BancorpBought 1,211 shares on 4/23/2024Ownership: 0.012%New Mexico Educational Retirement BoardSold 1,000 shares on 4/23/2024Ownership: 0.005%Eads & Heald Wealth ManagementSold 950 shares on 4/23/2024Ownership: 0.004%Summit Trail Advisors LLCBought 189 shares on 4/23/2024Ownership: 0.002%Oak Harbor Wealth Partners LLCBought 374 shares on 4/23/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: Edwards Lifesciences has shown consistent growth in its stock price, reaching a 52-week high of $95.27. The company's focus on structural heart disease and critical care monitoring products positions it well in the healthcare sector, which has long-term growth potential. Recent institutional investments in the company indicate confidence from major players in the market. Edwards Lifesciences' innovative transcatheter heart valve replacement products under the SAPIEN family offer minimally invasive solutions for aortic valve replacement. The company's strong financial health, with a current ratio of 3.38 and a quick ratio of 2.40, provides stability and liquidity for investors. Cons Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: The company's price-to-earnings ratio of 40.13 and price-to-earnings-growth ratio of 4.61 may indicate a relatively high valuation compared to industry peers. While the company has shown growth, there may be increased competition in the healthcare sector, leading to potential market share challenges. Fluctuations in healthcare regulations and reimbursement policies could impact Edwards Lifesciences' revenue and profitability. Market volatility and macroeconomic factors could affect the company's stock performance, making it susceptible to external economic conditions. Investors should consider the company's debt-to-equity ratio of 0.09 as part of their risk assessment when investing in Edwards Lifesciences. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com. EW Stock Analysis - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EW shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price target for 2024? 17 analysts have issued 12-month target prices for Edwards Lifesciences' shares. Their EW share price targets range from $57.00 to $107.00. On average, they expect the company's share price to reach $91.73 in the next twelve months. This suggests a possible upside of 4.6% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2024? Edwards Lifesciences' stock was trading at $76.25 at the start of the year. Since then, EW shares have increased by 15.1% and is now trading at $87.73. View the best growth stocks for 2024 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 10,450,000 shares, an increase of 23.8% from the February 29th total of 8,440,000 shares. Based on an average trading volume of 3,940,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 1.8% of the company's shares are short sold. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our EW earnings forecast. How can I listen to Edwards Lifesciences' earnings call? Edwards Lifesciences will be holding an earnings conference call on Thursday, April 25th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) announced its earnings results on Tuesday, February, 6th. The medical research company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. The medical research company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 23.56% and a net margin of 23.35%. The firm's quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.64 EPS. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Honeytree U.S. Equity ETF (BEEZ), Fundamentals First ETF (KNOW), Global X Aging Population ETF (AGNG), Guru Favorite Stocks ETF (GFGF), Tema Cardiovascular and Metabolics ETF (HRTS), IndexIQ Active ETF Trust - IQ Winslow Focused Large Cap Growth ETF (IWFG) and Fidelity Disruptive Medicine ETF (FMED). When did Edwards Lifesciences' stock split? Edwards Lifesciences's stock split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its first quarter 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of 0.620-0.660 for the period, compared to the consensus EPS estimate of 0.660. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Raymond James & Associates (0.29%), Sumitomo Mitsui Trust Holdings Inc. (0.27%), Raymond James Financial Services Advisors Inc. (0.19%), Factory Mutual Insurance Co. (0.08%), Allspring Global Investments Holdings LLC (0.05%) and Sarasin & Partners LLP (0.04%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More This page (NYSE:EW) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.